Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin

Pharmacotherapy

Volumn 20, Issue 5, 2000, Pages 589-592

  Eckart, Robert E ^a   Hospenthal, Duane R ^a   Fishbain, Joel T ^a  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GENTAMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TROVAFLOXACIN; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TISSUE LEVEL; EMBOLISM; ENDOCARDITIS; FEVER; HUMAN; LEUKOCYTOSIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; SEPSIS;

ADULT; ANTI-INFECTIVE AGENTS; ENDOCARDITIS, BACTERIAL; FLUOROQUINOLONES; HUMANS; LUNG ABSCESS; MALE; METHICILLIN; METHICILLIN RESISTANCE; NAPHTHYRIDINES; PENICILLINS; STAPHYLOCOCCAL INFECTIONS;

EID: 0034065467     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.6.589.35156     Document Type: Article

References (34)

1. Embil J, Ramotar K, Romance L, et al. Methicillin-resistant Staphylococcus aureus in tertiary care institutions on the Canadian prairies 1990-1992. Infect Control Hosp Epidemiol 1994;15:646-51.
2. Maguire GP, Arthur AD, Boustead PJ, Dwyer B, Currie BJ. Emerging epidemic of community-acquired methicillin-resistant Staphylococcus aureus infection in the Northern Territory. Med J Aust 1996;164:721-3.
3. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
4. Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996;23:255-9.
5. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34(6):1227-31.
6. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.
7. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
8. Neu HC, Davidson S, Briones F. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. Am J Med 1989;87(suppl 5A):209S-12.
9. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1947;40:634-51.
10. Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother 1997;40:205-11.
11. MacGowan AP. Moxifloxacin (Bay 12-8039): a new methoxy quinolone antibacterial. Exp Opin Invest Drugs 1999;8(2): 181-99.
12. Montanari MP, Prenna M, Mingoia M, Ripa S, Varaldo PE. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones. Chemotherapy 1998:44:85-93.
13. Evans ME, Titlow WB. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrob Agents Chemother 1998:42:7-27.
14. Evans ME, Titlow WB. Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin. J Antimicrob Chemother 1998;41(2):285-8.
15. Kaatz GW, Seo SM, Lamp KC, Bailey EM, Rybak MJ. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1992;36(6): 1192-7.
16. Maserati R, Cagni AE, Segú C. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Chemotherapy 1996;42:133-9.
17. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin susceptible or resistant Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1662-7.
18. Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1998;42(2):254-6.
19. Chambers HF, Liu QX, Chow LL, Hackbarth C. Efficacy of levofloxacin lor experimental aortic-valve endocarditis in rabbits infected with viridans group Streptococcus or Staphylococcus aureus. Antimicrob Agents Chemother 1999;43(11):2742-6.
20. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Amimicrob Agents Chemother 1999;43:77-84.
21. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995:274(21):1706-13.
22. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
23. Villar E, Mohammedi I, Duperret S, Bouffard Y, Bouletreau P. Community-acquired methicillin-resistant Staphylococcus aureus right-sided endocarditis in a non-addict patient with ventricular septal defect. Intensive Care Med 1999;25:236-7.
24. Dworkin RJ, Lee BL, Sande MA, Chambers HF. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 1989;2:1071-3.
25. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996;101:68-76.
26. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994;38(12):2702-9.
27. Entenza JM, Marchetti O, Glauser MP, Moreillon P. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob Agents Chemother 1998;42: 1889-94.
28. Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997;39:747-802.
29. 18F-labeling and biodistribution of a novel fluoroquinolone antimicrobial agent, trovafloxacin (CP 99.219). Nucl Med Biol 1996;23(8):995-8.
30. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996;23(suppl 1):S19-24.
31. Pennington JE, Reynolds HY. Pharmacokinetics of gentamicin sulfate in bronchial secretions. J Infect Dis 1975;131(2): 158-62.
32. Santré C, Georges H, Jacquier JM, et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Chemother 1995;39(1):264-7.
33. Bryant RE, Fox K, Oh G, Morthland VH. β-Lactam enhancement of aminoglycoside activity under conditions of reduced pH and oxygen tension that may exist in infected tissues. J Infect Dis 1992;165:676-82.
34. Verklin RM, Mandell GL. Alteration of effectiveness of amibiotics by anaerobiosis. J Lab Clin Med 1977;89(1):65-71.